Iovance Biotherapeutics, Inc. IOVA
11.00
0.20
1.85%
as of 25 Sep
- Market cap
- $4.9B
- P/E
- 0.0×
Follow IOVA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (40.36%) | (47.51%) | (55.50%) | (53.89%) |
+8 more TTM periods Free account |
|
| (31.76%) | (37.40%) | (42.88%) | (41.94%) | ||
ROIC |
(42.96%) | (55.59%) | (62.77%) | (64.83%) | |
Return on Tangible Assets |
(59.22%) | (75.53%) | (89.79%) | (92.48%) | |
Average Days of Receivables |
114.70 | 104.48 | 114.21 | 97.31 | |
Free Cash Flow per Share |
(0.66) | (0.73) | (0.94) | (0.97) | |
Free Cash Flow |
(296.39) | (305.02) | (336.24) | (351.82) | |
Capital Expenditures |
(32.21) | (34.23) | (33.84) | (28.68) | |
Piotroski F-Score |
5.00 | 3.00 | 4.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(25.56%) | (26.16%) | (30.38%) | (32.21%) | |
Accounts Receivable Turnover |
4.01 | 3.74 | 3.47 | 4.09 | |
Accounts Payable Turnover |
5.76 | 5.25 | 6.97 | 4.87 | |
Inventory Turnover |
3.18 | 2.79 | 3.36 | 3.39 | |
Average Days of Payables |
57.05 | 79.03 | 46.70 | 74.44 | |
Days of Inventory on Hand |
121.01 | 123.19 | 108.92 | 123.22 | |
Tax Rate |
(0.01) | 0.00 | (0.01) | 0.00 | |
Research and Development Expense of Revenue |
82.38% | 100.41% | 113.95% | 118.36% | |
Selling, General and Administrative Expense of Revenue |
45.90% | 51.63% | 57.81% | 63.05% | |
Share Based Compensation of Revenue |
14.38% | 17.48% | 23.37% | 32.24% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.91 | 0.77 | 0.77 | 0.81 | |
Depreciation/Fixed assets |
0.30 | 0.30 | 0.31 | 0.34 | |
Capex/Depreciation |
(0.82) | (0.86) | (0.84) | (0.66) | |
Revenue per Share |
0.72 | 0.68 | 0.74 | 0.69 | |
Operating CF per Share |
(0.59) | (0.65) | (0.85) | (0.89) | |
Capex per Share |
(0.07) | (0.08) | (0.09) | (0.08) | |
Capex to Sales |
0.10 | 0.12 | 0.13 | 0.11 | |
Net Profit Margin |
(89.09%) | (123.90%) | (148.38%) | (158.78%) |
Columns are period end dates